August 31, 2014 3:54 AM ET

Biotechnology

Company Overview of Origen Therapeutics, Inc.

Company Overview

Origen Therapeutics, Inc., a biotechnology company, develops products from avian transgenic animal technology. It provides human sequence polyclonal antibodies. The company also develops a technology platform based on the genetic engineering of chicken embryonic cells, which can be genetically modified in such a way that the introduced genes are stably expressed in adult birds. Origen Therapeutics, Inc. was incorporated in 1997 and is based in Emeryville, California.

5885 Hollis Street

Suite 370

Emeryville, CA 94608

United States

Founded in 1997

Phone:

510-597-5100

Fax:

650-558-7799

Key Executives for Origen Therapeutics, Inc.

President
Vice President of Finance & Business Development
Director of Research
Vice President of Research
Chief Scientific Officer
Age: 57
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Synbody Biotechnology, Inc. United States
Bridge to Life, Ltd. United States
AMPRO Products, Inc. United States
Rozetta-Cell Life Sciences, Inc. United States
QT Holdings Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Origen Therapeutics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.